Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$17.60
-$0.66(-1.42%)
At close: 4:00 PM EST
$17.60
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$13.70 - $61.07
Previous CloseN/A
Volume30.18K
Average Volume (3M)511.86K
Market Cap
$348.42M
Enterprise Value$85.73M
Total Cash (Recent Filing)$287.38M
Total Debt (Recent Filing)$1.94M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 06, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding18,712,128
10 Day Avg. Volume455,811
30 Day Avg. Volume511,858
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.53
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$84.83Price Target Upside381.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTectonic released positive topline data from Part B of the Phase 1b Group 2 PH trial, showcasing potential for TX45 across a broader range of PH-HF patients.
Drug Development StrategyTECX's decision to expand TX45 into another new indication is a strategically positive step that increases optionality.
Financial OutlookTectonic ended the quarter with a cash position of $306.2M, which is expected to support operations into 4Q28.
Bears Say
Comparative Trial OutcomesThe failed volenrelaxin trial casts a cloud over relaxin drug development, raising concerns about the entire drug class.
Investor SentimentShort interest is high at 33.6% of the float, which could indicate some investor skepticism or potential for volatility.
Trial ChallengesChallenges in the Re-PHIRE trial design could make it difficult to achieve its primary endpoint, influencing TECX negatively.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $348.42M.
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Nov 06, 2025 which is in 5 days.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.977 by -$0.093.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -1.06.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 18,712,128 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.977. Following the earnings report the stock price went up 1.779%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.83 (381.99% Upside)
$84.83 (381.99% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.56%
12-Months-Change
Fundamentals
Return on Equity
-29.32%
Trailing 12-Months
Asset Growth
52.29%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Tectonic Therapeutic (TECX) is a biotechnology company focused on discovering and developing novel therapeutics to treat complex diseases. The company operates primarily in the biopharmaceutical sector, leveraging cutting-edge technology and scientific research to create innovative drug candidates. Tectonic Therapeutic is committed to addressing unmet medical needs across various therapeutic areas, including oncology, immunology, and rare diseases.
TECX Stock 12 Month Forecast
Average Price Target
$84.83
▲(381.99% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
38.52% Insiders
13.07% Mutual Funds
<0.01% Other Institutional Investors
43.01% Public Companies and Individual Investors
Options Prices
Currently, No data available
---